Your session is about to expire
← Back to Search
Avutometinib + Defactinib for Non-Small Cell Lung Cancer(RAMP202 Trial)
RAMP202 Trial Summary
This trial will study whether a new drug is safe and effective for treating Non-small cell lung cancer that has come back.
- Non-Small Cell Lung Cancer
- KRAS Mutation
RAMP202 Trial Eligibility Criteria
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
RAMP202 Trial Timeline
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
RAMP202 Trial Design
Find a Location
Who is running the clinical trial?
- You have a heart condition or severe lung disease.You have other eye conditions at the same time.You are unable to swallow pills or tablets.You have a skin condition that needed treatment with medication taken by mouth or injection within the past year.You have recovered enough from any side effects caused by previous treatments.You must have received treatment for your condition before joining the study.You had cancer before, but it was treated and cured.You have brain tumors that are causing symptoms and require medication or other treatments.
- Group 1: Arm 1: avutometinib (VS-6766) monotherapy
- Group 2: Arm 2: avutometinib (VS-6766) in combination with defactinib
- Group 3: Arm 3: avutometinib (VS-6766) in combination with defactinib
- Group 4: Arm 4: avutometinib (VS-6766) in combination with defactinib
- Group 5: Arm 5:avutometinib (VS-6766) in combination with defactinib
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
In what areas has this trial been implemented?
"As of now, the trial is recruiting from 30 different sites located across America. Notable cities include Saint Louis, Chattanooga and Hackensack among others. It would be wise to select a location closest you so as to reduce travel commitments for participants."
What is the total participant count for this research endeavor?
"This research, funded by Verastem Inc., requires 100 qualified individuals. It will be conducted at Washington University School of Medicine in Saint Louis and Chattanooga Oncology Hematology Assoc. in Chattanooga, New Jerseyt Washington University School of Medicine in Saint Louis and Chattanooga Oncology Hematology Assoc. in Chattanooga, New Jersey."
What primary goals are researchers attempting to achieve through this clinical investigation?
"This clinical trial has two main objectives. The primary goal is to measure efficacy over a 24-week period, while the secondary outcomes evaluate Overall Response Rate (ORR), Duration of Response (DOR) and Progression Free Survival (PFS). These metrics are assessed by investigator assessments such as Complete/Partial Remission or Disease Progression."
Is recruitment for this research endeavor still being accepted?
"Indeed, the clinicaltrials.gov portal shows that this trial is presently recruiting patients - it was initially posted on December 31st 2020 and last updated July 19th 2022. The study requires 100 participants to be recruited from 30 different sites."
Are there any published accounts of VS-6766 being used in prior experiments?
"VS-6766 was initially examined by the ECOG-ACRIN Cancer Research Group in 2015. Presently, there are 9 active research projects and 7 completed trials that have been conducted regarding this medication – many of which occur within Saint Louis, MissouriN Cancer Research Group in 2015. Presently, there are 9 active research projects and 7 completed trials that have been conducted regarding this medication – many of which occur within Saint Louis, Missouri."
What have been the reported safety outcomes of VS-6766 usage?
"Our team at Power evaluated the safety of VS-6766 to be a 2 due to its Phase 2 status. This indicates that there is some evidence backing the drug's security, but none confirming effectiveness."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends